12:55 PM EDT, 10/29/2026 (MT Newswires) -- Molecular Partners (MOLN.SW) plans to cut up to 55 jobs, representing 44% of its current workforce, in light of its strategic focus on radiopharmaceuticals, according to a Thursday release. The clinical-stage biotechnology company has informed the Office for Economic Affairs of Kanton Zürich of its plan and has initiated a consultation process with employees in accordance with Swiss employment law. Molecular Partners expects to fully implement the changes by the second quarter of 2027, with cost reductions set to be fully effective early in the second half of the same year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.